Financial

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

Cradle provides a scientific AI software platform focused on protein engineeringBayer continues to utilize AI in R&D, reinforcing commitment to…

1 month ago

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

Cradle provides a scientific AI software platform focused on protein engineeringBayer continues to utilize AI in R&D, reinforcing commitment to…

1 month ago

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

Cradle provides a scientific AI software platform focused on protein engineeringBayer continues to utilize AI in R&D, reinforcing commitment to…

1 month ago

Precision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac Care

DUBLIN, Jan. 7, 2026 /PRNewswire/ -- LUMA Vision Ltd., a leader in cardiac 4D navigation and imaging, today announced the successful completion…

1 month ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate…

1 month ago

AMC Health Announces Breakthrough in AI-Driven Alert Precision for Virtual Care Program

New data science-driven alert framework expected to reduce clinician burden by 45% while preserving industry-leading outcomes, critical amid workforce shortages…

1 month ago

Quva Awarded National Outsourced Compounded Preparations Agreement with Premier, Inc.

SUGAR LAND, Texas, Jan. 6, 2026 /PRNewswire/ -- QuVa Pharma, Inc (Quva), a national, industry-leading provider of outsourced sterile injectable…

1 month ago